Mei Ri Jing Ji Xin Wen·2025-11-25 00:09Group 1 - Heptagon Pharma announced an update to its global strategic collaboration with AstraZeneca, focusing on the discovery and development of next-generation biotherapies, including antibody-drug conjugates (ADCs) and T-cell engagers (TCEs) [1] - AstraZeneca will nominate research projects to Heptagon Pharma annually for the next four years, granting them licensing options for these projects [1] - The collaboration reflects the strengthening partnership between Heptagon Pharma and AstraZeneca, highlighting the integration of Chinese biotech companies into the global pharmaceutical ecosystem [1] Group 2 - Prolog Pharma's subsidiary received a drug registration certificate for Cefdinir dry suspension, marking it as the first domestic generic drug approved under the consistency evaluation of quality and efficacy [2] - This approval allows Cefdinir to participate in national medical insurance negotiations, enhancing its market competitiveness [2] Group 3 - Sinovac's recombinant shingles vaccine has received clinical trial approval from the National Medical Products Administration, targeting individuals aged 40 and above [3] - The market for shingles vaccines in China is currently limited, with existing products facing low public willingness for vaccination [3] Group 4 - AstraZeneca announced a $2 billion investment to expand its manufacturing operations in Maryland, marking its fourth major manufacturing investment in the U.S. this year [4] - The company plans to invest $50 billion in the U.S. by 2030 to enhance its manufacturing and R&D capabilities, which is expected to create tens of thousands of jobs [4] Group 5 - Mandi International has submitted its application for listing on the Hong Kong Stock Exchange, focusing on skin health and weight management solutions, with its core brand being a hair loss treatment product [5] - Mandi has ranked first in the Chinese hair loss medication market for ten consecutive years, holding a market share of 57% in 2024 [5] - The company's revenue is highly dependent on a single product, making its IPO progress a point of interest for investors [5]